| Biotech Firm Admits Vaccine Manufacturing
Not Timely or Effective For Pandemics
Biotech firm Replikins Ltd., which has analyzed the H1N1 virus'
genomic data issued its latest biochemical analysis of the virus
suggesting the pandemic has peaked and that current biological
methods of vaccine production are ineffective.
The company has analyzed the H1N1 virus' genomic data from the
1918 pandemic through the prediction, outbreak, and progress of
the current H1N1 pandemic. The new data shows that the lethality
of the H1N1 ("Swine Flu") virus has dropped from its
peak of 3.7 (s.d. 4.5) during the virus's current outbreak in
the spring of 2009 to resting non-epidemic levels this week of
2.0 (s.d. 0.1). The H1N1 virus' infectivity count, however, remains
increased.
The company issued an interim advance report of this decrease
in lethality on September 30, 2009. That report has now been confirmed
by the current additional Replikins data and by the recent CDC
epidemiological reports of declining total hospitalizations and
deaths, and declining pediatric deaths from H1N1.
Without advance warning, the current biological methods of vaccine
production cannot possibly meet the growing needs of a human population
that today exceeds 6.7 billion. The current H1N1 Pandemic demonstrates
the inherent limitations of biological vaccines, which simply
do not permit the timely delivery of vaccine in sufficient quantities
before a "hit-and-run" emergent viral disease like H1N1
has come and gone.
Editor's note: This analysis by Replikins Ltd, regarding the
peaking of the pandemic, does incorporate any new changes to the
H1N1 virus including mutations now observed in North America,
and South America, Asia and Europe which have demonstrated a more
lethal fatality rate.
*
A full list of h1n1 vaccine ingredients, alerts and warnings.
Reference Source: prnewswire.com
November 26, 2009
 ...............................................................................................................
|
